author-photo

Neal D. Shore

University of Texas Southwestern Medical Center

588

Papers

19970

Citations

Citation Trend

Filter By

Papers (588) Sort By

Journal Conference Others

Pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus placebo plus CRT for patients (pts) with muscle-invasive bladder cancer (MIBC): The phase III KEYNOTE-992 study.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)

2021 Cancer Chemotherapy and Pharmacology
Show All
- Source
- Cite
- Save
Citations (1)
Efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with de novo (M1) metastatic hormone-sensitive prostate cancer (mHSPC) versus progression to mHSPC (M0): Post hoc analysis of the phase III ARCHES trial.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Treating the patient and not just the cancer: therapeutic burden in prostate cancer.

2021 Prostate Cancer and Prostatic Diseases
Show All
- Source
- Cite
- Save
Citations (3)
PD13-10 UNIVERSAL GERMLINE TESTING OF PROSTATE CANCER PATIENTS: ARE GENETIC TESTING GUIDELINES AN IMPEDIMENT TO PRECISION THERAPY?

2021 The Journal of Urology
Show All
- Source
- Cite
- Save
Citations (0)
Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial.

2021 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (1)
The Courage study: A first-in-human phase 1 study of the CBP/p300 inhibitor FT-7051 in men with metastatic castration-resistant prostate cancer.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study.

2021 Clinical Genitourinary Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Clinical outcomes and patient (pt) profiles in REASSURE: an observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC)

2021
Show All
- Source
- Cite
- Save
Citations (0)
628P Universal germline testing of prostate cancer patients: Are genetic testing guidelines an aid or an impediment to precision therapy?

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)